EA201100063A1 - СПОСОБ ПОЛУЧЕНИЯ ПИРИДО-ПИРИМИДИНОВЫХ ИНГИБИТОРОВ mTOR КИНАЗЫ, ИХ СОЛЕВЫХ ФОРМ И ИХ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ - Google Patents
СПОСОБ ПОЛУЧЕНИЯ ПИРИДО-ПИРИМИДИНОВЫХ ИНГИБИТОРОВ mTOR КИНАЗЫ, ИХ СОЛЕВЫХ ФОРМ И ИХ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВInfo
- Publication number
- EA201100063A1 EA201100063A1 EA201100063A EA201100063A EA201100063A1 EA 201100063 A1 EA201100063 A1 EA 201100063A1 EA 201100063 A EA201100063 A EA 201100063A EA 201100063 A EA201100063 A EA 201100063A EA 201100063 A1 EA201100063 A1 EA 201100063A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- kinazes
- pyrido
- pyrimidin
- obtaining
- salt forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Обеспечиваются способ получения соединения формулы 1применение указанного способа для получения соединения формулы 5или его фосфатной, сульфатной, гидросульфатной, малатной, цитратной, тартратной или фумаратной соли и применение фумаратной соли в композиции для применения в терапии.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7418808P | 2008-06-20 | 2008-06-20 | |
US15235009P | 2009-02-13 | 2009-02-13 | |
PCT/GB2009/050695 WO2009153597A2 (en) | 2008-06-20 | 2009-06-18 | Composition and process - 356 |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201100063A1 true EA201100063A1 (ru) | 2011-10-31 |
EA019092B1 EA019092B1 (ru) | 2014-01-30 |
Family
ID=41051136
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201100063A EA019092B1 (ru) | 2008-06-20 | 2009-06-18 | СПОСОБ ПОЛУЧЕНИЯ ПИРИДО-ПИРИМИДИНОВЫХ ИНГИБИТОРОВ mTOR КИНАЗЫ, ИХ СОЛЕВЫХ ФОРМ |
Country Status (27)
Country | Link |
---|---|
US (1) | US8198441B2 (ru) |
EP (1) | EP2303875B1 (ru) |
JP (1) | JP5607614B2 (ru) |
KR (1) | KR101668497B1 (ru) |
CN (1) | CN102137860B (ru) |
AR (1) | AR072263A1 (ru) |
AU (1) | AU2009261688B2 (ru) |
BR (1) | BRPI0914912A2 (ru) |
CA (1) | CA2728183C (ru) |
CL (1) | CL2010001488A1 (ru) |
CO (1) | CO6351729A2 (ru) |
CR (1) | CR11859A (ru) |
DO (1) | DOP2010000391A (ru) |
EA (1) | EA019092B1 (ru) |
EC (1) | ECSP10010696A (ru) |
ES (1) | ES2398423T3 (ru) |
HK (1) | HK1155160A1 (ru) |
IL (1) | IL210074A (ru) |
MX (1) | MX2010014230A (ru) |
MY (1) | MY172107A (ru) |
NI (1) | NI201000225A (ru) |
PE (1) | PE20110147A1 (ru) |
SV (1) | SV2010003770A (ru) |
TW (1) | TWI441821B (ru) |
UY (1) | UY31917A (ru) |
WO (1) | WO2009153597A2 (ru) |
ZA (1) | ZA201101861B (ru) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2715181A1 (en) * | 2008-02-21 | 2009-08-27 | Astrazeneca Ab | Combination therapy 238 |
TWI441824B (zh) | 2010-12-16 | 2014-06-21 | Hoffmann La Roche | 三環pi3k抑制劑化合物及其使用方法 |
CN104803922A (zh) * | 2015-03-14 | 2015-07-29 | 长沙深橙生物科技有限公司 | 一种嘧啶衍生物的制备方法 |
CN106008559B (zh) * | 2015-03-25 | 2020-10-16 | 中国科学院上海药物研究所 | 取代吡啶并嘧啶类化合物的合成工艺 |
TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
WO2019180141A1 (en) | 2018-03-23 | 2019-09-26 | Bayer Aktiengesellschaft | Combinations of rogaratinib |
SG11202012447YA (en) | 2018-06-15 | 2021-01-28 | Navitor Pharm Inc | Rapamycin analogs and uses thereof |
IL293549A (en) | 2019-12-05 | 2022-08-01 | Anakuria Therapeutics Inc | Rapamycin analogs and their uses |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4560685A (en) * | 1984-06-18 | 1985-12-24 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | 2-Piperazino-pteridines useful as antithrombotics and antimetastatics |
DE3445298A1 (de) | 1984-12-12 | 1986-06-12 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue pteridine, verfahren zu ihrer herstellung und deren verwendung als zwischenprodukte oder als arzneimittel |
US5990117A (en) * | 1998-04-15 | 1999-11-23 | Cell Pathways, Inc. | Method for inhibiting neoplastic cells and related conditions by exposure to quinazoline derivatives |
HU229958B1 (hu) | 1999-09-07 | 2015-03-30 | Syngenta Participations Ag | Herbicid vegyületek, ezeket tartalmazó készítmények, eljárás a vegyületek előállítására, valamint eljárás gyomnövények irtására |
WO2001083456A1 (fr) | 2000-04-27 | 2001-11-08 | Yamanouchi Pharmaceutical Co., Ltd. | Derives d'heteroaryle condenses |
US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
EP1575951B1 (en) | 2002-12-06 | 2014-06-25 | Debiopharm International SA | Heterocyclic compounds, methods of making them and their use in therapy |
US20050009817A1 (en) | 2003-04-30 | 2005-01-13 | Jennifer Savoy | Substituted heteroaryls |
GB0428475D0 (en) | 2004-12-30 | 2005-02-02 | 4 Aza Bioscience Nv | Pyrido(3,2-D)pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
JP2008543888A (ja) | 2005-06-24 | 2008-12-04 | ギリアード サイエンシーズ, インコーポレイテッド | ピリド(3,2−d)ピリミジン、およびC型肝炎を治療するのに有用な医薬組成物 |
US20070128658A1 (en) * | 2005-11-14 | 2007-06-07 | Blackwell Helen E | Fluorescent dyes, methods and uses thereof |
JP5161102B2 (ja) | 2005-11-22 | 2013-03-13 | クドス ファーマシューティカルズ リミテッド | mTOR阻害剤としてのピリドピリミジン、ピラゾピリミジンおよびピリミドピリミジン誘導体 |
SI2057156T1 (sl) * | 2006-08-23 | 2017-06-30 | Kudos Pharmaceuticals Limited | Derivati 2-metilmorfolin pirido-, pirazo- in pirimido-pirimidina kot inhibitorji mTOR |
CN101896180A (zh) | 2007-10-15 | 2010-11-24 | 阿斯利康(瑞典)有限公司 | 组合059 |
-
2009
- 2009-06-18 CA CA2728183A patent/CA2728183C/en active Active
- 2009-06-18 KR KR1020117001287A patent/KR101668497B1/ko active IP Right Grant
- 2009-06-18 TW TW098120503A patent/TWI441821B/zh not_active IP Right Cessation
- 2009-06-18 JP JP2011514132A patent/JP5607614B2/ja active Active
- 2009-06-18 MY MYPI2010006040A patent/MY172107A/en unknown
- 2009-06-18 US US12/487,294 patent/US8198441B2/en active Active
- 2009-06-18 EP EP09766158A patent/EP2303875B1/en active Active
- 2009-06-18 UY UY0001031917A patent/UY31917A/es not_active Application Discontinuation
- 2009-06-18 CN CN2009801303297A patent/CN102137860B/zh active Active
- 2009-06-18 ES ES09766158T patent/ES2398423T3/es active Active
- 2009-06-18 AU AU2009261688A patent/AU2009261688B2/en not_active Ceased
- 2009-06-18 EA EA201100063A patent/EA019092B1/ru not_active IP Right Cessation
- 2009-06-18 PE PE2010001171A patent/PE20110147A1/es not_active Application Discontinuation
- 2009-06-18 WO PCT/GB2009/050695 patent/WO2009153597A2/en active Application Filing
- 2009-06-18 BR BRPI0914912A patent/BRPI0914912A2/pt not_active Application Discontinuation
- 2009-06-18 MX MX2010014230A patent/MX2010014230A/es active IP Right Grant
- 2009-06-19 AR ARP090102264A patent/AR072263A1/es unknown
-
2010
- 2010-12-16 IL IL210074A patent/IL210074A/en active IP Right Grant
- 2010-12-20 CL CL2010001488A patent/CL2010001488A1/es unknown
- 2010-12-20 DO DO2010000391A patent/DOP2010000391A/es unknown
- 2010-12-20 EC EC2010010696A patent/ECSP10010696A/es unknown
- 2010-12-20 SV SV2010003770A patent/SV2010003770A/es not_active Application Discontinuation
- 2010-12-20 CR CR11859A patent/CR11859A/es not_active Application Discontinuation
- 2010-12-20 NI NI201000225A patent/NI201000225A/es unknown
-
2011
- 2011-01-19 CO CO11005447A patent/CO6351729A2/es not_active Application Discontinuation
- 2011-03-10 ZA ZA2011/01861A patent/ZA201101861B/en unknown
- 2011-09-05 HK HK11109366.4A patent/HK1155160A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201100063A1 (ru) | СПОСОБ ПОЛУЧЕНИЯ ПИРИДО-ПИРИМИДИНОВЫХ ИНГИБИТОРОВ mTOR КИНАЗЫ, ИХ СОЛЕВЫХ ФОРМ И ИХ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ | |
EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
EA200970935A1 (ru) | Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа | |
EA200970932A1 (ru) | Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа | |
EP4233869A3 (en) | Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders | |
CY1111721T1 (el) | Ακυλαμινοπυραζολια ως αναστολεις fgfr | |
EA201200318A1 (ru) | Гетероциклические оксимы | |
MY148688A (en) | 2-methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as mtor inhibitors | |
EA201391263A1 (ru) | Комбинированные терапии гематологических опухолей | |
MX2009005413A (es) | Formas cristalinas del acido zoledronico. | |
MY150547A (en) | Protein kinase inhibitors | |
EA201101672A1 (ru) | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина | |
EA200700637A1 (ru) | Соли донепезила, подходящие для получения фармацевтических композиций | |
RU2010144637A (ru) | Замещенные гамма-лактамы в качестве терапевтических агентов | |
RU2013148815A (ru) | Комбинации соединений-ингибиторов акт и абиратерона и способы применения | |
EA200970611A1 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы | |
EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
EA201792597A3 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
ATE543492T1 (de) | Behandlung von lungenkrebs | |
EA201071352A1 (ru) | Трициклические азотсодержащие соединения и их применение в качестве бактерицидных средств | |
CY1112638T1 (el) | Χρηση των παραγωγων ινδολιου ως ενεργοποιητες νurr-1 για την θεραπεια νοσου ραrκινsον | |
SMT201300112B (it) | Sale citrato di 9E-15-(2-pirrolidin-1-il-etossi)-7,12,25-triossa-19,21,24-triaza-tetracicloÄ18.3.1.1(2,5).1(14,18)Üesacos a-1(24),2,4,9,14,16,18(26),20,22-nonaene | |
ATE369366T1 (de) | S-tenatoprazolnatrium-monohydrat-salz und dessen verwendung in form eines protonenpumpenhemmers | |
MY160005A (en) | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt | |
EA200801003A1 (ru) | Фармацевтически приемлемые соли и гидраты ризедроновой кислоты |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |